Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.
Their goal is to shape the future of medical imaging, enhance the standard of care, and improve patient outcomes by incorporating advancements in AI and digital solutions.
Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
